Rankings
▼
Calendar
ADMA Q4 2025 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena
ADMA
ADMA Biologics, Inc.
$4B
Q4 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$139M
+18.4% YoY
Gross Profit
$89M
63.8% margin
Operating Income
$63M
45.1% margin
Net Income
$49M
35.5% margin
EPS (Diluted)
$0.20
QoQ Revenue Growth
+3.7%
Cash Flow
Operating Cash Flow
$36M
Free Cash Flow
$35M
Stock-Based Comp.
$5M
Balance Sheet
Total Assets
$624M
Total Liabilities
$147M
Stockholders' Equity
$477M
Cash & Equivalents
$88M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$139M
$118M
+18.4%
Gross Profit
$89M
$63M
+40.2%
Operating Income
$63M
$38M
+63.7%
Net Income
$49M
$112M
-55.9%
Geographic Segments
UNITED STATES
$137M
99%
Non-US
$2M
1%
← FY 2025
All Quarters